uploads///medical _

What Analysts Recommend for Pfizer and Eli Lilly in February

By

Feb. 12 2019, Updated 1:47 p.m. ET

Stock price movements

On February 8, Pfizer (PFE) closed at $42.23, 1.27% higher than its previous closing price, 27.20% higher than its 52-week low of $33.20, and 9.12% below its 52-week high of $46.47. Its market capitalization was $248.10 billion, and its trailing-12-month and forward PE ratios are 22.75x and 13.83x, respectively.

Since its fourth-quarter earnings release, Pfizer stock has risen 4.48% from $40.42 on January 29 to $42.23 on February 8. The company surpassed its consensus revenue estimate by $80 million and consensus earnings per share estimate by $0.01 in the fourth quarter.

Article continues below advertisement

On February 8, Eli Lilly (LLY) closed at $119.60, 1.79% higher than its previous closing price, 62.30% higher than its 52-week low of $73.69, and 1.84% below its 52-week high of $121.84. Its market capitalization was $124.47 billion, and its trailing-12-month and forward PE ratios are 38.17x and 18.29x, respectively.

Since its fourth-quarter earnings release, Eli Lilly’s stock rose by 0.28% from $119.27 on February 6 to $119.60 on February 8. The company surpassed its consensus revenue estimate by $140 million but missed the consensus EPS estimate by $0.01 in the fourth quarter. Pfizer is trading at a lower trailing PE ratio as well as a lower forward PE ratio as compared to Eli Lilly.

Analysts’ recommendations and target price

The 12-month consensus recommendation for Pfizer and Eli Lilly is “buy.” Of the 14 analysts covering Pfizer, two recommend “strong buy,” five recommend “buy,” six recommend “hold,” and one analyst recommends a “strong sell.” Their 12-month target price is $44.46, 5.28% higher than its last closing price on February 8. The highest target price estimate for the company is $53, and the lowest is $35.

Of the 16 analysts covering Eli Lilly, two recommend “strong buy,” five recommend “buy,” and nine recommend “hold.” Their 12-month target price is $120.07, 0.39% higher than its last closing price on February 8. The highest target price estimate for the company is $143, and the lowest is $93.

Next, we’ll look at the revenue growth trajectories of Pfizer and Eli Lilly.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.